– USA, VA – ReAlta Life Sciences, Inc., a clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, today announced the appointment of Emma Reeve to its Board of Directors, effective immediately.
“We are very pleased to welcome Emma Reeve to our Board of Directors,” said Buzz Heidt, Chairman of ReAlta’s Board of Directors. “As ReAlta continues to advance our programs towards commercial launch in markets around the world, Emma’s diverse global experience and deep knowledge of capital markets and financial strategies will help guide and strengthen our plans to deliver novel therapies to the patients that urgently need them.”
About Emma Reeve
Emma Reeve is an accomplished biopharmaceutical executive with more than 30 years of global financial experience across pharmaceutical, medical device, and bio-pharma companies. Most recently, she served as CFO of Constellation Pharmaceuticals, Inc., a development-stage oncology company, before its acquisition by MorphoSys AG in 2021. She led Constellation’s IPO in 2018.
Before Constellation, Emma Reeve acted as interim CFO and Corporate Controller of Parexel International, a global biopharmaceutical services company, where she was responsible for all aspects of finance, investor relations, procurement, and facilities. In this role, she led the finance aspects of a sell-side process which culminated in an agreement to take the company private in a $5 billion leveraged buy-out. Earlier in her career, Emma Reeve served as CFO of both Inotek Pharmaceuticals and Aton Pharma. Additionally, she held senior finance and operational roles at Bristol Myers Squibb, Merck, and Novartis.
“I am impressed with the remarkable progress ReAlta has made to advance multiple programs into the clinic,” commented Emma Reeve. “I am excited to take on this role and contribute to the company’s mission to address life threatening acute inflammatory and rare diseases.”
Emma Reeve is Chair of the Board of Editas Medicine and serves on the Board of PTC Therapeutics and Aadi Bioscience, all public biotechnology companies. In addition, she serves on the Board of Directors for Cardurion Pharma. Ms. Reeve holds a B.Sc. in computer science from Imperial College, University of London, and is an associate of the Institute of Chartered Accountants in England and Wales.
About ReAlta Life Sciences
ReAlta Life Sciences, Inc. is a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening acute inflammatory and rare diseases. The Company’s EPICC peptides are based on research into the human astrovirus, HAstV-1, which causes a non-inflammatory, self-limiting gastroenteritis unique among viruses by inhibiting components of the innate immune system. ReAlta’s therapeutic peptides leverage these virus-derived mechanisms to rebalance complement and inflammatory processes in the body. The company’s pipeline is led by RLS-0071, which has received IND clearance by the U.S. Food and Drug Administration for the treatment of acute exacerbations of chronic obstructive pulmonary disease and acute graft-versus-host disease, and IND clearance, Orphan Drug Designation, and Fast Track Designation by the FDA, and Orphan Drug Designation by the European Medicines Agency, for the treatment of hypoxic-ischemic encephalopathy. The company launched in 2018 and is located in Norfolk, Virginia.
For more: https://realtalifesciences.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.